Orphan Drugs Sound Small but Can Lead to Big Drug Spending
High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.
High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.
PCMA Launches New Campaign Aimed at Repealing the Medicare Prescription Drug Rebate Rule March 1, 2021 ARTICLE (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. PBMS ARE REDUCING PRESCRIPTION DRUG COSTS FOR PATIENTS… We hope this
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
According to a new analysis, there are now 70 PBMs operating in a diverse and competitive marketplace.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal. “We applaud the Biden Administration for delaying the
©2024 PCMA. All Rights Reserved.